Opus Genetics, Inc. Increase (Decrease) in Notes Receivables
Opus Genetics, Inc. (IRD) reported Increase (Decrease) in Notes Receivables of $18.68 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2014-03-21.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivables · last filed 2014-03-21
- Opus Genetics, Inc. increase (decrease) in notes receivables for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in notes receivables for the quarter ending 2012-09-30 was $4.67K, a 33.33% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in notes receivables for the quarter ending 2012-06-30 was $7.00K, a 0.01% increase year-over-year.
- Opus Genetics, Inc. increase (decrease) in notes receivables for the quarter ending 2012-03-31 was $7.01K, a 0.01% decline year-over-year.
- Opus Genetics, Inc. increase (decrease) in notes receivables for fiscal 2012 was $18.68K, a 33.33% decline from fiscal 2011.
- Opus Genetics, Inc. increase (decrease) in notes receivables for fiscal 2011 was $28.02K.
- Opus Genetics, Inc. increase (decrease) in notes receivables for fiscal 2010 was -$46.70K.
- Opus Genetics, Inc. increase (decrease) in notes receivables for fiscal 2009 was $0.00.
| Period end | Increase (Decrease) in Notes Receivables 3 month | Increase (Decrease) in Notes Receivables 6 month | Increase (Decrease) in Notes Receivables 9 month | Increase (Decrease) in Notes Receivables 12 month | Increase (Decrease) in Notes Receivables 132 month | Increase (Decrease) in Notes Receivables 135 month |
|---|---|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $4.67K derived: sum of 2 quarters · filed 2014-03-21 | $11.68K derived: sum of 3 quarters · filed 2014-03-21 | $18.68K 10-K · filed 2014-03-21 | ||
| 2012-09-30 | $4.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $11.68K derived: sum of 2 quarters · filed 2013-11-13 | $18.68K 10-Q · filed 2013-11-13 | $25.69K derived: sum of 4 quarters · filed 2013-11-13 | ||
| 2012-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $14.01K 10-Q · filed 2013-08-12 | $21.02K derived: sum of 3 quarters · filed 2013-08-12 | $28.02K derived: sum of 4 quarters · filed 2013-08-12 | -$4.67K 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $7.01K 10-Q · filed 2013-05-09 | $14.01K derived: sum of 2 quarters · filed 2013-05-09 | $21.02K derived: sum of 3 quarters · filed 2013-05-09 | $28.02K derived: sum of 4 quarters · filed 2013-05-09 | -$11.68K 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $7.01K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | $14.01K derived: sum of 2 quarters · filed 2013-03-22 | $21.02K derived: sum of 3 quarters · filed 2013-03-22 | $28.02K 10-K · filed 2013-03-22 | ||
| 2011-09-30 | $7.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $14.01K derived: sum of 2 quarters · filed 2012-11-08 | $21.02K 10-Q · filed 2012-11-08 | $28.02K derived: sum of 4 quarters · filed 2012-11-08 | ||
| 2011-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | $14.01K 10-Q · filed 2012-08-08 | $21.02K derived: sum of 3 quarters · filed 2012-08-08 | $23.35K derived: sum of 4 quarters · filed 2012-08-08 | ||
| 2011-03-31 | $7.01K 10-Q · filed 2012-05-09 | $14.01K derived: sum of 2 quarters · filed 2012-05-09 | $16.35K derived: sum of 3 quarters · filed 2012-05-09 | |||
| 2010-12-31 | $7.01K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | $9.34K derived: sum of 2 quarters · filed 2012-03-16 | -$46.70K 10-K · filed 2012-03-16 | |||
| 2010-09-30 | $2.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$53.71K 10-Q · filed 2011-11-09 | ||||
| 2010-06-30 | -$56.05K 10-Q · filed 2011-08-09 | |||||
| 2009-12-31 | $0.00 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |